ArticleMolecular brain2022
Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort.
Article in Molecular brain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The identification of cognitive impairment in Parkinson's disease using biofluids, neuroimaging, and artificial intelligence.Frontiers in neuroscience · 2024Pooled it
- Competing endogenous RNA (ceRNA) networks in Parkinson's disease: A systematic review.Frontiers in cellular neuroscience · 2023Pooled it
- Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development.Journal of Parkinson's disease · 2026Article
- Cognitive and motor profiles in biologically defined Parkinson's and Alzheimer's disease.Journal of Parkinson's disease · 2026Article
- Review
- Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism.Current neurology and neuroscience reports · 2026Review
- Characteristics and mechanisms of cognitive impairment in Parkinson disease.Nature reviews. Neurology · 2026Review
- Towards a Biologically Defined Diagnosis: Incorporating Pathophysiological Measures Into Parkinson's Disease Clinical Criteria.Parkinson's disease · 2026Review
- Parkinson's Disease: Immunometabolic Control Points Across Neural, Vascular, and Peripheral Systems.Parkinson's disease · 2026Review
- Neuronal PARIS-STAT3 axis drives tau pathology and glial activation in Alzheimer's disease.bioRxiv : the preprint server for biology · 2025Article
- Nuclear Medicine Imaging Biomarkers in Parkinson's Disease: Past, Present, and Future Directions.Medical sciences (Basel, Switzerland) · 2025Review
- Cognitive Phenotyping of Parkinson's Disease Patients Via Digital Analysis of Spoken Word Properties.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- CSF phospho-tau levels at Parkinson's disease onset predict the risk for development of motor complications.Journal of neurology · 2025Article
- Longitudinal Multimodal Functional Imaging: An Essential Tool for Visualizing Pathologic Progression in Parkinson's Disease.Journal of movement disorders · 2025Article
- Cola acuminata extract's inhibition of NLRP3 inflammasome in THP-1 cells as a potential treatment option for Parkinson's disease.Metabolic brain disease · 2025Article
- Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD.Annals of clinical and translational neurology · 2025Article
- Impact of 6-OHDA injection and microtrauma in the ratHistology and histopathology · 2025Article
- The role ofFrontiers in neuroscience · 2025Review
- Using machine learning for detection of Parkinson's disease and mild cognitive impairment.PloS one · 2025Article
- Glutathione S-transferase polymorphisms (GSTM1/GSTT1) outcomes in clinical profile and treatment responsiveness among Tunisian cohort of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The accumulation of beta amyloid in the brain has a complex and poorly understood impact on the progression of Parkinson's disease pathology and much controversy remains regarding its role, specifically in cognitive decline symptoms. Some studies have found increased beta amyloid burden is associated with worsening cognitive impairment in Parkinson's disease, especially in cases where dementia occurs, while other studies failed to replicate this finding. To better understand this relationship, we examined a cohort of 25 idiopathic Parkinson's disease patients and 30 healthy controls from the Parkinson's Progression Marker Initiative database. These participants underwent [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.